For over 22 years pancreatica.org has provided current, credible, and comprehensive information to those in need.
Cancer Patient’s Alliance is a 501(c)(3) non-profit organization. All donations are tax-deductible.

94% of all revenue goes towards our programs, with only 6% towards MANAGEMENT AND GENERAL EXPENSES.

Monthly Archives: August 2013

Hepatitis as a Risk Factor for Pancreatic Cancer

A number of odd or non-intuitive relationships between apparently unrelated variables and pancreatic cancer (ductal adenocarcinoma of the pancreas) are beginning to emerge – including ABO blood status, and now some forms of hepatitis. In the World Journal of Gastroenterology from July 14, 2013, Chen and colleagues from the Southern Medical University, in Guangzhou, China […]

Cryotherapy plus Biologic Therapy for Advanced Cancer of the Pancreas

It is the impression of this author that in the past decade or so the quantity and quality of published medical research coming from China has increased rather remarkably. This has included challenges to “standard” established practice – with innovative ideas particularly on the treatment of pancreatic cancer (ductal adenocarcinoma of the pancreas). Now comes […]

Pancreatic Cancer Pre-clinical study (from an Amazonian tree): Geissospermum vellosii

As mentioned in this blog on several times, we are always on the lookout for interesting scientific studies related to the treatment of pancreatic cancer (ductal adenocarcinoma of the pancreas) with alternative or complementary treatment approaches. The July 2013 issue of the journal Oncology Reports features research by Chen and colleagues from the University of […]

Bacterial Causes for Pancreatic Cancer? (dental association yet again)

Interesting research over recent years into risk factors for ductal adenocarcinoma of the pancreas have yielded the usual suspects – and a number of somewhat surprising candidates for pancreatic cancer. These include the smoking of tobacco products, onset of diabetes, large intake of alcohol, pancreatitis, (possibly) obesity, ABO blood typing status, and even infections such […]

Afinitor plus Temodar for Neuroendocrine Tumors?

There are few hard and fast rules for the medical treatment of patients with metastatic pancreatic neuroendocrine tumors. Two agents which have shown promise include everolimus (Afinitor ~ Novartis) and temozolomide (Temodar ~ Merck). An article by Kulke and colleagues at Harvard Medical School and the associated Dana-Farber Cancer Institute in Boston as published in […]